Any content you receive is for information purposes only. Always conduct your own research. *Sponsored See Why Paul Prescott Has (VNRX) On His Radar For Tomorrow—Wednesday, May 6, 2026
Don’t Miss The Next Breakout—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email.
Watch For Our (VNRX) Coverage To Begin Early.
Put (VNRX) On Your Watchlist Before Tomorrow Morning…
May 5, 2026
(VNRX) Just Hit Our Radar—Here's Why We're Watching Tomorrow Morning
Dear Reader, A tiny blood sample… and doctors could gain immediate insight into a life-threatening condition. Street Ideas is watching VolitionRx Limited (NYSE American: VNRX) following its latest breakthrough update. That’s part of why (VNRX) is now the top name on our watchlist heading into tomorrow morning—Wednesday, May 6, 2026. But keep in mind, after a recent restructuring, (VNRX) has less than 7M shares listed as available to the public. When companies have small floats like this, the potential exists for big moves if demand begins to swing. And with several analysts covering this one, we think (VNRX) deserves a serious look. What the Analysts Are Saying…
Justin Walsh at Jones maintains a Bullish Rating with a $60 target on (VNRX), according to TipRanks, which suggests over 2,500% upside potential from its recent $2.27 range. Yi Chen at H.C. Wainwright holds a Bullish Rating with a $20 target, according to TipRanks, which suggests over 700% upside potential. Steven Ralston, CFA at Zacks SCR, has issued a DCF-based valuation of $16.83 per share, which suggests over 600% upside potential — with the primary target driver being the probability-weighted value of licensing deals across (VNRX)’s three human diagnostic pillars. What Is VolitionRx?
(VNRX) develops blood-based diagnostic tests built on its proprietary Nucleosomics™ platform — the science of measuring nucleosomes, chromatin fragments that circulate in the bloodstream as a biological signal of disease activity. 
The company is headquartered in Henderson, Nevada, and operates research facilities in Belgium, with a team boasting hundreds of years of combined industry experience and 15+ years working together. (VNRX)’s flagship product portfolio runs across five pillars:
Nu.Q® Cancer – focused on lung cancer screening and disease management Capture-Seq™ – designed for multi-cancer early detection using pure tumor-derived DNA isolation Nu.Q® NETs – targets sepsis and diseases related to NETosis Nu.Q® Vet – used for cancer screening in dogs and cats Nu.Q® Discover – supports nucleosome-based research applications The company holds 68 patents granted with coverage to 2044, across 56 patent families. The business model is deliberately asset-light — (VNRX) licenses its IP to partners with large installed bases and commercial infrastructure, collecting upfront payments, milestone payments, and recurring royalties. That model has already been validated in the veterinary space, where licensing partners include IDEXX, Antech, and Fujifilm Vet Systems. Over $23M in licensing has been received to date.
Volition’s Core Platforms Address Over $30B In
Combined Market Potential…
The total addressable markets across (VNRX)’s pillars are substantial. Nu.Q® Cancer sits in a $4B laboratory-developed screening market. Capture-Seq™ targets a $23B multi-cancer early detection market. Nu.Q® NETs addresses an over $3B ICU/ED sepsis diagnostics segment — particularly compelling given that sepsis accounts for 1-in-5 deaths worldwide and costs U.S. healthcare alone $62B per year. The Nu.Q® Vet division operates in a $170M non-regulated animal testing licensing market where the company has already crossed its first $1M in revenue. Clinical Data Continues to Accumulate
(VNRX)’s March 25, 2026 announcement revealed that its Capture-Seq™ platform achieved over 95% sensitivity for Stage I and II cancers with 95% specificity — in a blinded independent validation cohort. That is a world-first: the isolation of pure tumor-derived DNA from a liquid biopsy, removing 99.7% of background DNA and achieving an 18,000% enrichment. Separately, the company's April 29, 2026 breakthrough demonstrated that nucleosomes can be detected from a finger-prick blood sample — a development that could radically expand the addressable market for sepsis testing. In veterinary diagnostics, (VNRX) completed full automation of the Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan in March 2026, enabling high-throughput processing across Fujifilm's network of 10 central reference labs and access to an estimated 11,000 Japanese veterinary facilities. Financial Position and Licensing Pipeline For full-year 2025, (VNRX) reported revenue of $1.7M, up 40% from the prior year, while Q4 revenue rose 133% year over year. At the same time, operating expenses fell by $4.8M, or 17%, and net cash used in operating activities declined 24% to $19.7M. Management expects cash costs to fall another 25–30% in 2026 as the company continues its cost-reduction plan. (VNRX) also strengthened its near-term funding position after year-end, receiving $5.4M in net proceeds from equity sales, $1.9M from a convertible note and warrant, and $1M in non-dilutive funding from Walloon Region agencies, with another $0.9M expected over the next 12 months. (VNRX) is currently in confidential licensing discussions with approximately 10 large diagnostic and liquid biopsy companies worldwide. The executive team brings deep expertise across epigenetics, oncology diagnostics, and life sciences commercialization, underpinned by more than 15 years working together on the Nu.Q® platform. 7 Reasons (VNRX) Has My Full Attention Ahead Of Tomorrow Morning—Wednesday, May 6, 2026…
1. Analyst Targets: Multiple analyst targets suggest over 600% to 2,500% upside potential from (VNRX)’s recent $2.27 range, including $60, $20, and $16.83 targets. 2. Small Float: With less than 7M public shares after a recent restructuring, (VNRX)’s small float could witness the potential for big moves if demand begins to swing. 3. Finger-Prick Test: The April 29, 2026 update showed (VNRX) can detect nucleosomes from a finger-prick blood sample for sepsis testing. 4. Cancer Data: Capture-Seq™ from (VNRX) achieved over 95% sensitivity for Stage I and II cancers with 95% specificity in a blinded validation cohort. 5. Licensing Talks: Management says (VNRX) is in confidential discussions with about 10 large diagnostic and liquid biopsy companies worldwide. 6. Cost Discipline: Revenue rose 40% in 2025 while operating expenses fell 17%, giving (VNRX) a stronger cost-control story heading into 2026. 7. Patent Base: With 68 granted patents across 56 patent families, (VNRX) has IP coverage extending to 2044. Put (VNRX) On Your Watchlist Before Tomorrow Morning…
Taken together, these developments paint a picture of a company at a potentially pivotal stage. From its small float, to analyst targets that suggest over 600% to 2,500% upside potential, (VNRX) has our full focus right now. At the same time, the underlying science continues to advance—highlighted by a finger-prick approach to sepsis detection and strong early-stage cancer data—while a growing patent portfolio and ongoing discussions with major diagnostic players suggest broader validation may be building behind the scenes. Layer in improving financial discipline, with rising revenue and reduced expenses, and it becomes clear why (VNRX) is starting to stand out across multiple fronts. This is the type of setup where technology, positioning, and timing are all beginning to intersect. We’ll be watching (VNRX) very closely tomorrow morning. Pull up (VNRX) before the night is over. And keep an eye out for my next update, it could be hitting bright and early. Sincerely, Paul Prescott
Co-Founder & Managing Editor
Street Ideas Newsletter
|
